NCT06691321 Caspofungin for Pneumocystis Pneumonia in PLWHIV.
| NCT ID | NCT06691321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Instituto Nacional de Enfermedades Respiratorias |
| Condition | HIV-1-infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-08-01 |
| Primary Completion | 2025-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2023-08-01 with a primary completion date of 2025-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section). * Have clinical laboratory and virological diagnostic laboratory studies at the time of admission. * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.: Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism. Exclusion Criteria: * With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B). * Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.
Contact & Investigator
Santiago Avila, PhD
PRINCIPAL INVESTIGATOR
Center for Research in Infectious Diseases (CIENI)
Frequently Asked Questions
Who can join the NCT06691321 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying HIV-1-infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06691321 currently recruiting?
Yes, NCT06691321 is actively recruiting participants. Contact the research team at xavier.flores@cieni.org.mx for enrollment information.
Where is the NCT06691321 trial being conducted?
This trial is being conducted at Mexico City, Mexico.
Who is sponsoring the NCT06691321 clinical trial?
NCT06691321 is sponsored by Instituto Nacional de Enfermedades Respiratorias. The principal investigator is Santiago Avila, PhD at Center for Research in Infectious Diseases (CIENI). The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.